Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

被引：0
|
作者：
Zelniker, T. A. [1 ,2 ]
Raz, I. [3 ]
Mosenzon, O. [3 ]
Dwyer, J. P. [4 ]
Heerspink, H. J. L. [5 ]
Cahn, A. [3 ]
Im, K. [1 ,2 ]
Bhatt, D. L. [1 ,2 ]
Leiter, L. A. [6 ]
McGuire, D. K. [7 ]
Wilding, J. P. H. [8 ]
Gause-Nilsson, I. A. M. [9 ]
Langkilde, A. M. [9 ]
Sabatine, M. S. [1 ,2 ]
Wiviott, S. D. [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Hadassah Univ, Med Ctr, Jerusalem, Israel
[4] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[5] Univ Med Ctr Groningen, Groningen, Netherlands
[6] Univ Toronto, Toronto, ON, Canada
[7] Univ Texas Southwestern Med Sch, Dallas, TX USA
[8] Univ Liverpool, Liverpool, Merseyside, England
[9] AstraZeneca, Gothenburg, Sweden
来源：
EUROPEAN HEART JOURNAL | 2019年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
192
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [41] The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial
    McEwan, Phil
    Morgan, Angharad R.
    Boyce, Rebecca
    Bergenheim, Klas
    Gause-Nilsson, Ingrid A. M.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Johansson, Peter A.
    Mosenzon, Ofri
    Cahn, Avivit
    Wilding, John P. H.
    DIABETES OBESITY & METABOLISM, 2021, 23 (04): : 1020 - 1029
  • [42] Galectin-3 and Progression of Kidney Disease in Patients With Type 2 Diabetes Mellitus: Analyses From the DECLARE-TIMI 58 Trial
    Haller, Paul
    Wiviott, Stephen
    Berg, David
    Jarolim, Petr
    Goodrich, Erica
    Bhatt, Deepak
    Cahn, Avivit
    Gause-Nilsson, Ingrid
    Leiter, Lawrence
    McGuire, Darren
    Raz, Itamar
    Wilding, John
    Sabatine, Marc
    Morrow, David
    CIRCULATION, 2024, 150
  • [43] Effect of dapagliflozin on renal and cardiac function in patients with type 2 diabetes and albuminuria: a randomised study
    Eickhoff, M. K.
    Olsen, F. J.
    Frimodt-Moller, M.
    Diaz, L. J.
    Jensen, M. T.
    Rossing, P.
    Persson, F.
    DIABETOLOGIA, 2018, 61 : S299 - S300
  • [44] Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from theLEADERrandomized trial
    Mosenzon, Ofri
    Bain, Stephen C.
    Heerspink, Hiddo J. L.
    Idorn, Thomas
    Mann, Johannes F. E.
    Persson, Frederik
    Pratley, Richard E.
    Rasmussen, Soren
    Rossing, Peter
    von Scholten, Bernt Johan
    Raz, Itamar
    DIABETES OBESITY & METABOLISM, 2020, 22 (11): : 2077 - 2088
  • [45] A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58
    Berg, David
    Wiviott, Stephen D.
    Raz, Itamar
    Kamanu, Frederick
    Im, KyungAh
    Cahn, Avivit
    Mosenzon, Ofri
    Bhatt, Deepak L.
    Jarolim, Petr
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John
    Huo, Yong
    Lopez-Sendon, Jose L.
    Ardissino, Diego
    Gause-Nilsson, Ingrid A.
    Sabatine, Marc S.
    Morrow, David A.
    CIRCULATION, 2020, 142
  • [46] The effect of dapagliflozin on renal function in patients with type 2 diabetes
    Donald Elliott Kohan
    Paola Fioretto
    Kristina Johnsson
    Shamik Parikh
    Agata Ptaszynska
    Lisa Ying
    Journal of Nephrology, 2016, 29 : 391 - 400
  • [47] Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study
    Norhammar, Anna
    Bodegard, Johan
    Nystrom, Thomas
    Thuresson, Marcus
    Rikner, Klas
    Nathanson, David
    Eriksson, Jan W.
    DIABETES OBESITY & METABOLISM, 2019, 21 (12): : 2651 - 2659
  • [48] The effect of dapagliflozin on renal function in patients with type 2 diabetes
    Kohan, Donald Elliott
    Fioretto, Paola
    Johnsson, Kristina
    Parikh, Shamik
    Ptaszynska, Agata
    Ying, Lisa
    JOURNAL OF NEPHROLOGY, 2016, 29 (03) : 391 - 400
  • [49] EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES IN PATIENTS AT HIGH RISK OF ADVANCED LIVER FIBROSIS: POST HOC ANALYSES FROM THE DECLARE- TIMI 58 TRIAL
    Oscarsson, Jan
    Huhn, Monika
    Gause-Nilsson, Ingrid Am
    Wiviott, Stephen D.
    Moura, Filipe A.
    Wilding, John P. H.
    Cernea, Simona
    Van Gaal, Luc
    Cahn, Avivit
    Bhatt, Deepak L.
    McGuire, Darren K.
    Johansson, Peter A.
    Sjostrom, C. David
    HEPATOLOGY, 2023, 78 : S1177 - S1178
  • [50] Cardiovascular outcome according to renal status in Finnish patients with type 2 diabetes
    Hellman, Tapio A.
    Skare, Ole-Christian
    Lee, Christopher
    Wagner, Uta
    Vikkula, Johanna
    Hallfors, Jenni
    Laatikainen, Outi
    Lassenius, Mariann I.
    Metsarinne, Kaj
    DIABETES EPIDEMIOLOGY AND MANAGEMENT, 2022, 8
12345